Charles River Laboratories International (CRL)
(Delayed Data from NYSE)
$200.61 USD
-1.07 (-0.53%)
Updated Dec 4, 2023 04:00 PM ET
After-Market: $200.64 +0.03 (0.01%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth F Momentum D VGM
Fundamental Charts
About EPS Diluted (Quarterly)
The company's quarterly EPS Diluted value tell you how the company is doing this quarter. Diluted earnings per share offer a worst-case scenario -- what the company's stock would look like if the company had to immediately issue every share it had promised in stock options or convertible bonds. A company's diluted earnings per share is calculated by dividing the company's annual profit by its number of outstanding shares. A company with $1 million in profit and 1 million shares of outstanding stock has an EPS of $1.
CRL 200.61 -1.07(-0.53%)
Will CRL be a Portfolio Killer in December?
Zacks Investment Research is releasing its prediction for CRL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CRL
Charles River (CRL) Gains on Price & Volume Growth Amid FX Woe
Charles River (CRL) Backs the Quest to Cure SPG56 via New Deal
CRL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Charles River (CRL) Widens CliniPrime GMP Suite With New Launch
Charles River (CRL) to Advance AI Drug Discovery With New Pact
Charles River's (CRL) Q3 Earnings Beat, Margins Decline
Other News for CRL
Creightons swings to half-year profit on cost-cutting measures
Insider Sell: EVP Joseph Laplume Sells Shares of Charles River Laboratories International Inc (CRL)
CRL Crosses Above Key Moving Average Level
Charles River and Genetic Cures for Kids Announce Gene Therapy Manufacturing Collaboration
Charles River Laboratories to Present at Evercore ISI Investor Conference